Premium
Antimycobacterial and Synergistic Effects of 18β‐Glycyrrhetinic Acid or Glycyrrhetinic acid‐30‐piperazine in Combination with Isoniazid, Rifampicin or Streptomycin against Mycobacterium bovis
Author(s) -
Zhou Xuezhang,
Zhao Li,
Liu Xiaoming,
Li Xueqiang,
Jia Fang,
Zhang Yuyan,
Wang Yujiong
Publication year - 2012
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.3536
Subject(s) - antimycobacterial , isoniazid , streptomycin , rifampicin , pyrazinamide , pharmacology , mycobacterium tuberculosis , chemistry , piperazine , minimum inhibitory concentration , microbiology and biotechnology , tuberculosis , biology , antibiotics , medicine , pathology
18ß‐Glycyrrhetinic acid (18ßGA) is a major bioactive component of liquorice with known activity. In this study, we found that both 18ßGA and its derivative glycyrrhetinic acid‐30‐piperazine (PGA), have potent antimycobacterial properties against the drug‐susceptible and drug‐resistant Mycobacterium bovis . More importantly, they exhibited synergistic effects with the first‐line drugs isoniazid (INH), rifampicin (RIF) and streptomycin (SM) against clinical M. bovis isolates, including drug‐resistant strains. In combination with a subinhibitory concentration of 18ßGA, the minimum inhibitory concentrations (MICs) of the anti‐tuberculosis agents decreased, ranging from 4‐ to 16‐, 4‐ to 8‐ and 4‐ to 8‐fold for INH (fractional inhibitory concentration index (FICI) 0.125–0.375), RIF (FICI 0.118–0.281) and SM (FICI 0.094–0.275), respectively. In the presence of PGA, MICs for the first‐line agents resulted in a 4–16‐fold decrease for INH (FICI 0.094–0.266, RIF (FICI 0.114–0.313) and SM (FICI 0.094–0.281). Additionally, the MICs of 18ßGA or PGA alone showed significant decreases ranging from 8‐ to 16‐, 8‐ to 64‐ and 8‐ to 128‐fold in the presence of INH, RIF and SM, respectively. These findings indicate that 18ßGA and its derivatives might serve as potential therapeutic compounds for future antimycobacterial drug development. Copyright © 2011 John Wiley & Sons, Ltd.